RxDoctor Payments Data

Lon Baratz, MD

Internal Medicine · Rochester, NYNPI 1487614350

Payments from drug & device makers

$2,216in general payments, 2019–2025

Across 143 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$358
  • Gilead$292
  • Lilly USA, LLC$250
  • Astellas Pharma US Inc$224
  • Pfizer$157
  • AbbVie$150
  • plus $785 from 15 others

What the payments were for

  • Food & beverage$2,10995%
  • Education$1075%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,216 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$24,784
Medicare patients
94
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala58$219,376
DovatoDolutegravir Sodium/Lamivudine25$70,360
TivicayDolutegravir Sodium17$60,552
OzempicSemaglutide48$57,423
DescovyEmtricitabine/Tenofov Alafenam23$55,769
EliquisApixaban46$53,933
TriumeqAbacavir/Dolutegravir/Lamivudi14$49,106
JardianceEmpagliflozin37$40,942
JanuviaSitagliptin Phosphate34$34,010
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)28$20,864
IsentressRaltegravir Potassium11$20,456
XareltoRivaroxaban14$19,594
FarxigaDapagliflozin Propanediol13$16,183
MyrbetriqMirabegron26$14,535
TrulicityDulaglutide11$14,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$292$275,14581 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq$358$180,01756 claims
Novo NordiskOzempic, Rybelsus$147$69,05060 claims
MerckJanuvia, Isentress$59$54,46645 claims
PfizerEliquis$157$53,93346 claims
Boehringer IngelheimJardiance$41$40,94237 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$134$28,51361 claims
Johnson & JohnsonXarelto$25$19,59414 claims
AstraZenecaFarxiga, Symbicort$71$18,83624 claims
Astellas Pharma US IncMyrbetriq$224$14,53526 claims
Lilly USA, LLCTrulicity$250$14,40111 claims
AbbVieLinzess$150$12,24423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →